Mitotech metabolic disorder candidate

A preclinical, orally bioavailable small molecule developed by Mitotech for the treatment of obesity and metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH). This mitochondria-targeted compound employs a dual mechanism of action: it acts as a mitochondrial uncoupler to increase energy expenditure and reduce fat accumulation, while simultaneously functioning as a potent antioxidant to protect organ tissues from ferroptosis and inflammation. By specifically targeting the mitochondrial inner membrane, the drug aims to correct metabolic imbalances and prevent the cellular damage that drives the progression of metabolic diseases. The candidate is designed to address the underlying mitochondrial dysfunction associated with metabolic syndrome.

Other names

Mitotech obesity candidateMitotech mitochondrial uncoupler